The concept of the inflammasome and its rheumatologic implications

Joint Bone Spine

Volumn 81, Issue 5, 2014, Pages 398-402

  So, Alexander ^a   Busso, Nathalie ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Auto inflammatory disorders; Gout; IL1 ; Inflammasome

Indexed keywords

CALCIUM PHOSPHATE; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; URATE; CARRIER PROTEIN; NLRP3 PROTEIN, HUMAN;

CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); CRYSTAL; DENDRITIC CELL; DISEASE ACTIVITY SCORE; GENE MUTATION; HUMAN; NONHUMAN; OSTEOARTHRITIS; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS; AUTOIMMUNE DISEASE; GOUT; IMMUNOLOGY; MACROPHAGE; PATHOPHYSIOLOGY; PHYSIOLOGY; RHEUMATIC DISEASE;

AUTOIMMUNE DISEASES; CARRIER PROTEINS; DENDRITIC CELLS; GOUT; HUMANS; INFLAMMASOMES; MACROPHAGES; RHEUMATIC DISEASES;

EID: 84927689265     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2014.02.009     Document Type: Short Survey

References (49)

1. Martinon F., Burns K., Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002, 10:417-426.
2. Joosten L.A., Ea H.K., Netea M.G., et al. Interleukin-1beta activation during acute joint inflammation: a limited role for the NLRP3 inflammasome in vivo. Joint Bone Spine 2011, 78:107-110.
3. So A., De Smedt T., Revaz S., et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007, 9:R28.
4. Ghosh P., Cho M., Rawat G., et al. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care Res 2013, 65:1381-1384.
5. Ottaviani S., Molto A., Ea H.K., et al. Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res Ther 2013, 15:R123.
6. Schumacher H.R., Evans R.R., Saag K.G., et al. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: Results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res 2012, 64:1462-1470.
7. Terkeltaub R., Sundy J.S., Schumacher H.R., et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009, 68:1613-1617.
8. So A., De Meulemeester M., Pikhlak A., et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010, 62:3064-3076.
9. Schlesinger N., Mysler E., Lin H.Y., et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 2011, 70:1264-1271.
10. Announ N., Palmer G., Guerne P.A., et al. Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine 2009, 76:424-426.
11. Ottaviani S., Brunier L., Sibilia J., et al. Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: a report of 16 cases and review of the literature. Joint Bone Spine 2013, 80:178-182.
12. Molto A., Ea H.K., Richette P., et al. Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis. Joint Bone Spine 2012, 79:621-623.
13. Zufferey P., So A. A pilot study of IL-1 inhibition in acute calcific periarthritis of the shoulder. Ann Rheum Dis 2013, 72:465-467.
14. Joosten L.A., Netea M.G., Mylona E., et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1beta production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum 2010, 62:3237-3248.
15. Zhang Y., Chen C., Choi H., et al. Purine-rich foods intake and recurrent gout attacks. Ann Rheum Dis 2012, 71:1448-1453.
16. Choi H.K., Atkinson K., Karlson E.W., et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004, 363:1277-1281.
17. Masters S.L., Simon A., Aksentijevich I., et al. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Ann Rev Immunol 2009, 27:621-668.
18. Lachmann H.J., Lowe P., Felix S.D., et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009, 206:1029-1036.
19. Tassi S., Carta S., Delfino L., et al. Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1beta secretion. Proc Natl Acad Sci USA 2010, 107:9789-9794.
20. Hawkins P.N., Lachmann H.J., McDermott M.F. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003, 348:2583-2584.
21. Alexander T., Klotz O., Feist E., et al. Successful treatment of acute visual loss in Muckle-Wells syndrome with interleukin 1 receptor antagonist. Ann Rheum Dis 2005, 64:1245-1246.
22. Lachmann H.J., Kone-Paut I., Kuemmerle-Deschner J.B., et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009, 360:2416-2425.
23. Hoffman H.M., Throne M.L., Amar N.J., et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008, 58:2443-2452.
24. Hoffman H.M., Rosengren S., Boyle D.L., et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004, 364:1779-1785.
25. Ter Haar N., Lachmann H., Ozen S., et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 2012.
26. Pascual V., Allantaz F., Arce E., et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005, 201:1479-1486.
27. Naumann L., Feist E., Natusch A., et al. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease. Ann Rheum Dis 2010, 69:466-467.
28. Wendling D., Prati C., Aubin F. Anakinra treatment of SAPHO syndrome: short-term results of an open study. Ann Rheum Dis 2012, 71:1098-1100.
29. Krause K., Weller K., Stefaniak R., et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy 2012, 67:943-950.
30. Pascual V., Allantaz F., Patel P., et al. How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets. Immunol Rev 2008, 223:39-59.
31. Ruperto N., Brunner H.I., Quartier P., et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012, 367:2396-2406.
32. Giampietro C., Ridene M., Lequerre T., et al. Anakinra in adult-onset still's disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res 2013, 65:822-826.
33. Pizzirani C., Falzoni S., Govoni M., et al. Dysfunctional inflammasome in Schnitzler's syndrome. Rheumatology (Oxford) 2009.
34. Migliorini P., Corso I.D., Tommasi C., et al. Free circulating interleukin-18 is increased in Schnitzler syndrome: a new autoinflammatory disease?. Eur Cytokine Netw 2009, 20:108-111.
35. van den Berg W.B. Arguments for interleukin 1 as a target in chronic arthritis. Ann Rheum Dis 2000, 59:i81-i84.
36. Fontalba A., Martinez-Taboada V., Gutierrez O., et al. Deficiency of the NF-kappaB inhibitor caspase activating and recruitment domain 8 in patients with rheumatoid arthritis is associated with disease severity. J Immunol 2007, 179:4867-4873.
37. Kastbom A., Verma D., Eriksson P., et al. Genetic variation in proteins of the cryopyrin inflammasome influences susceptibility and severity of rheumatoid arthritis (the Swedish TIRA project). Rheumatology (Oxford) 2008, 47:415-417.
38. Kastbom A., Johansson M., Verma D., et al. CARD8 p.C10X polymorphism is associated with inflammatory activity in early rheumatoid arthritis. Ann Rheum Dis 2010, 69:723-726.
39. Ben Hamad M., Cornelis F., Marzouk S., et al. Association study of CARD8 (p.C10X) and NLRP3 (p.Q705K) variants with rheumatoid arthritis in French and Tunisian populations. Int J Immunogenet 2012, 39:131-136.
40. Kolly L., Karababa M., Joosten L.A., et al. Inflammatory role of ASC in antigen-induced arthritis is independent of caspase-1. NALP-3, and IPAF. J Immunol 2009, 183:4003-4012.
41. Yamazaki H., Takeoka M., Kitazawa M., et al. ASC plays a role in the priming phase of the immune response to type II collagen in collagen-induced arthritis. Rheumatol Int 2012, 32:1625-1632.
42. Hasegawa M., Imamura R., Kinoshita T., et al. ASC-mediated NF-kappaB activation leading to interleukin-8 production requires caspase-8 and is inhibited by CLARP. J Biol Chem 2005, 280:15122-15130.
43. Hasegawa M., Imamura R., Motani K., et al. Mechanism and repertoire of ASC-mediated gene expression. J Immunol 2009, 182:7655-7662.
44. Kolly L., Busso N., Palmer G., et al. Expression and function of the NALP3 inflammasome in rheumatoid synovium. Immunology 2010, 129:178-185.
45. Chevalier X., Goupille P., Beaulieu A.D., et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2009, 61:344-352.
46. Jin C., Frayssinet P., Pelker R., et al. NLRP3 inflammasome plays a critical role in the pathogenesis of hydroxyapatite-associated arthropathy. Proc Natl Acad Sci USA 2011, 108:14867-14872.
47. Bougault C., Gosset M., Houard X., et al. Stress-induced cartilage degradation does not depend on the NLRP3 inflammasome in human osteoarthritis and mouse models. Arthritis Rheum 2012, 64:3972-3981.
48. Pontillo A., Girardelli M., Kamada A.J., et al. Polimorphisms in inflammasome genes are involved in the predisposition to systemic lupus erythematosus. Autoimmunity 2012, 45:271-278.
49. Panchanathan R., Duan X., Arumugam M., et al. Cell type and gender-dependent differential regulation of the p202 and Aim2 proteins: implications for the regulation of innate immune responses in SLE. Mol Immunol 2011, 49:273-280.